Dipyrithione inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in macrophages and protects against endotoxic shock in mice

FEBS Letters

Volumn 582, Issue 12, 2008, Pages 1643-1650

  Liu, Ziwen ^a   Fan, Yumei ^c   Wang, Yu ^a   Han, Cui ^a   Pan, Yu ^b   Huang, Huang ^b   Ye, Ying ^b   Luo, Lan ^b   Yin, Zhimin ^a  

^a NANJING NORMAL UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c Biochemistry and Molecular Biology of Hebei Province   (China)

Author keywords

COX 2; Dipyrithione; Endotoxic shock; iNOS; Lipopolysaccharide; STAT1

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOOXYGENASE 2; DIPYRITHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME RELEASE; ENZYME REPRESSION; MACROPHAGE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPTIC SHOCK; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED ICR; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; PYRIDINES; SHOCK, SEPTIC; STAT1 TRANSCRIPTION FACTOR; UP-REGULATION;

BACTERIA (MICROORGANISMS); MUS;

EID: 43549084328     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.04.016     Document Type: Article

References (47)

1. Rangel-Frausto M.S., Pittet D., Costigan M., Hwang T., Davis C.S., and Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS). J. Am. Med. Assoc. 273 (1995) 117-123
2. Balk R.A. Severe sepsis and septic shock. Crit. Care Clin. 16 (2000) 179-192
3. Richards M.J., Edwards J.R., Culver D.H., and Gaynes R.P. Nosocomial infections in medical intensive care units in the United States. Crit. Care Med. 27 (1999) 887-892
4. Szekanecz Z., and Koch A.E. Macrophages and their products in rheumatoid arthritis. Curr. Opin. Rheumatol. 19 (2007) 289-295
5. Victor V.M., Rocha M., and De la Fuente M. Regulation of macrophage function by the antioxidant N-acetylcysteine in mouse-oxidative stress by endotoxin. Int. Immunopharmacol. 3 (2003) 97-106
6. Noguchi S., Nakatsuka M., Konishi H., Kamada Y., Chekir C., and Kudo T. Nafamostat mesilate suppresses NF-κB activation and NO overproduction in LPS-treated macrophages. Int. Immunopharmacol. 3 (2003) 1335-1344
7. Turini M.E., and DuBois R.N. Cyclooxygenase-2: a therapeutic target. Annu. Rev. Med. 53 (2002) 35-37
8. Moncada S. Nitric oxide: discovery and impact on clinical medicine. J.R. Soc. Med. 92 (1999) 164-169
9. MacMicking J., Xie Q.W., and Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15 (1997) 323-350
10. Guo J.Y., Huo H.R., Yang Y.X., Li C.H., Liu H.B., Zhao B.S., Li L.F., Ma Y.Y., Guo S.Y., and Jiang T.L. 2-Methoxycinnamaldehyde reduces IL-1β-induced prostaglandin production in rat cerebral endothelial cells. Biol. Pharm. Bull. 29 (2006) 2214-2221
11. Surh Y.J., Chun K.S., Cha H.H., Han S.S., Keum Y.S., Park K.K., and Lee S.S. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 480-481 (2001) 243-268
12. Park S.W., Sung M.W., Heo D.S., Inoue H., Shim S.H., and Kim K.H. Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines. Oncogene 24 (2005) 6689-6698
13. Kim S.F., Huri D.A., and Snyder S.H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 310 (2005) 1966-1970
14. Kim J.B., Han A.R., Park E.Y., Kim J.Y., Cho W., Lee J., Seo E.K., and Lee K.T. Inhibition of LPS-induced iNOS, COX-2 and cytokines expression by poncirin through the NF-kappaB inactivation in RAW 264.7 macrophage cells. Biol Pharm Bull. 30 (2007) 2345-2351
15. Yun K.J., Kim J.Y., Kim J.B., Lee K.W., Jeong S.Y., Park H.J., Jung H.J., Cho Y.W., Yun K., and Lee K.T. Inhibition of LPS-induced NO and PGE(2) production by asiatic acid via NF-kappaB inactivation in RAW 264.7 macrophages: possible involvement of the IKK and MAPK pathways. Int Immunopharmacol. 8 (2008) 431-441
16. Kim J.H., Kim D.H., Baek S.H., Lee H.J., Kim M.R., Kwon H.J., and Lee C.H. Rengyolone inhibits inducible nitric oxide synthase expression and nitric oxide production by down-regulation of NF-kappaB and p38 MAP kinase activity in LPS-stimulated RAW 264.7 cells. Biochem. Pharmacol. 71 (2006) 1198-1205
17. Chan E.D., and Riches D.W. IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am. J. Physiol. Cell Physiol. 280 (2001) C441-C450
18. Jacobs A.T., and Ignarro L.J. Lipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW 264.7 macrophages. J. Biol. Chem. 276 (2001) 47950-47957
19. Gao J.J., Filla M.B., Fultz M.J., Vogel S.N., Russell S.W., and Murphy W.J. Autocrine/paracrine IFN-alphabeta mediates the lipopolysaccharide-induced activation of transcription factor Stat1alpha in mouse macrophages: pivotal role of Stat1alpha in induction of the inducible nitric oxide synthase gene. J. Immunol. 161 (1998) 4803-4810
20. Fan Y.M., Chen H., Qiao B., Luo L., Ma H., Li H., Jiang J.H., Niu D.Z., and Yin Z.M. Opposing effects of ERK and p38 MAP kinases on HeLa cell apoptosis induced by dipyrithione. Mol. Cell 23 (2007) 30-38
21. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Tew K.D., Pincus M.R., Sardana M., Henderson C.J., Wolf C.R., Davis R.J., and Ronai Z. Regulation of JNK singaling by GSTp. EMBO J. 18 (1999) 1321-1334
22. Marchini C., Angeletti M., Eleuteri A.M., Fedeli A., and Fioretti E. Aspirin modulates LPS-induced nitric oxide release in rat glial cells. Neurosci. Lett. 381 (2005) 86-91
23. Korhonen R., Lahti A., Kankaanranta H., and Moilanen E. Nitric oxide production and signaling in inflammation. Curr. Drug Targets Inflamm. Allergy 4 (2005) 471-479
24. Guo L., Guo H., Gao C., Mi Z., Russell W.B., and Kuo P.C. STAT1 acetylation inhibits inducible nitric oxide synthase expression in interferon-gamma-treated RAW264.7 murine macrophages. Surgery 142 (2007) 156-162
25. Bolli R., Dawn B., and Xuan Y.T. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc. Med. 13 (2003) 72-79
26. Xuan Y.T., Guo Y., Zhu Y., Han H., Langenbach R., Dawn B., and Bolli R. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J. Mol. Cell Cardiol. 35 (2003) 525-537
27. Xue B., Wu Y., Yin Z., Zhang H., Sun S., Yi T., and Luo L. Regulation of lipopolysaccharide-induced inflammatory response by glutathione S-transferase P1 in RAW264.7 cells. FEBS Lett. 579 (2005) 4081-4087
28. Jang B.C., Paik J.H., Kim S.P., Shin D.H., Song D.K., Park J.G., Suh M.H., Park J.W., and Suh S.I. Catalase induced expression of inflammatory mediators via activation of NF-kappaB, PI3K/AKT, p70S6K, and JNKs in BV2 microglia. Cell Signal. 17 (2005) 625-633
29. Baeuerle P.A., and Henkel T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12 (1994) 141-179
30. Barnes P.J. Nuclear factor-kappa B. Int. J. Biochem. Cell Biol. 29 (1997) 867-870
31. Doose C.A., Szaleniec M., Behrend P., Müller A., and Jastorff B. Chromatographic behavior of pyrithiones. J. Chromatogr. A 1052 (2004) 103-110
32. Malhotra G.G., and Zatz J.L. Investigation of nail permeation enhancement by chemical modification using water as a probe. J. Pharm. Sci. 91 (2002) 312-332
33. Glauser M.P., Zanetti G., Baumgartner J.D., and Cohen J. Septic shock: pathogenesis. Lancet 338 (1991) 732-736
34. Rainsford K.D. Anti-inflammatory drugs in the 21st century. Subcell. Biochem. 42 (2007) 3-27
35. Remick D.G., and Ward P.A. Evaluation of endotoxin models for the study of sepsis. Shock 24 (2005) 7-11
36. Hurley J.C. Endotoxemia: methods of detection and clinical correlates. Clin. Microbiol. Rev. 8 (1995) 268-292
37. Weinberg J.B., Fermor B., and Guilak F. Nitric oxide synthase and cyclooxygenase interactions in cartilage and meniscus: relationships to joint physiology, arthritis, and tissue repair. Subcell. Biochem. 42 (2007) 31-62
38. Wang H.Q., and Smart R.C. Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-alpha expression but not tumor promotion. J. Cell Sci. 112 (1999) 3497-3506
39. Kim S.H., Kim J., and Sharma R.P. Inhibition of p38 and ERK MAP kinases blocks endotoxin-induced nitric oxide production and differentially modulates cytokine expression. Pharmacol. Res. 49 (2004) 433-439
40. Chen Z., Hagler J., Palombella V.J., Melandri F., Scherer D., Ballard D., and Maniatis T. Signal-induced site specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Gene. Dev. 9 (1995) 1586-1597
41. Krappmann D., Wegener E., Sunami Y., Esen M., Thiel A., Mordmuller B., and Scheidereit C. The IκB kinase complex and NF-κB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. Mol. Cell. Biol. 24 (2004) 6488-6500
42. Shuai K., Stark G.R., Kerr I.M., and Darnell Jr. J.E. A single phosphotyrosine residue of Stat1 required for gene activation by interferon-γ. Science 261 (1993) 1744-1746
43. Gao J., Morrison D.C., Parmely T.J., Russell S.W., and Murphy W.J. An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. J. Biol. Chem. 272 (1997) 1226-1230
44. Meraz M.A., White J.M., Sheehan K.C.F., Bach E.A., Rodig S.J., Dighe A.S., Kaplan D.H., Riley J.K., Greenlund A.C., Campbell D., et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the Jak-Stat signaling pathway. Cell 84 (1996) 431-442
45. Salvemini D., Misko T.P., Masferrer J.L., Seibert K., Currie M.G., and Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc. Natl. Acad. Sci. USA 90 (1993) 7240-7244
46. Salvemini D., Seibert K., Masferrer J.L., Misko T.P., Currie M.G., and Needleman P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J. Clin. Invest. 93 (1994) 1940-1947
47. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97-120